Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506382 | 0.97 | CNR1 (0.39) | CNR1TSHRNPC1LMNAXBP1 | |
| SCHEMBL4524975 | 0.93 | HIF1A (0.42) | CNR1TSHRNPC1LMNAXBP1 | |
| SCHEMBL4512837 | 0.92 | CNR1 (0.46) | CNR1TSHRNPC1LMNAXBP1 | |
| SCHEMBL4522615 | 0.91 | HKDC1 (0.41) | TSHRNPC1LMNAMAPK1CDK1 | |
| SCHEMBL4529595 | 0.89 | TSHR (0.39) | CNR1TSHRNPC1LMNAXBP1 | |
| SCHEMBL4523527 | 0.89 | CNR1 (0.40) | CNR1TSHRNPC1LMNAXBP1 | |
| SCHEMBL4524872 | 0.89 | CNR1 (0.45) | CNR1TSHRNPC1LMNAXBP1 | |
| SCHEMBL4517383 | 0.88 | CNR1 (0.37) | CNR1TSHRNPC1LMNAXBP1 | |
| SCHEMBL4524524 | 0.88 | CDK1 (0.34) | LMNAMAPK1CDK1CCNB1CCNE1 | |
| SCHEMBL4505926 | 0.87 | CNR1 (0.38) | CNR1TSHRNPC1LMNAXBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | CNR1 18/4885TSHR 915/4885NPC1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.